Skip to main content
OpenTrials
Completed

NCT Number: NCT02105311

Effect of Selective Laser Trabeculoplasty Versus Travoprost on Circardian Intraocular Pressure

The investigators conduct this study to access the effect of selective laser trabeculoplasty on 24-hour circadian tension curves of patients with open-angle glaucoma, normal tension glaucoma and ocular hypertension. This treatment effect is compared with that of the prostaglandin analogue, travoprost.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Songklanagarind Hospital

Hat Yai, Changwat Songkhla, 90110, Thailand

About this study

Selective laser trabeculoplasty is an effective treatment for lowering intraocular pressure in patients with open-angle glaucoma. Clinical evaluations of its effectiveness in individual patients usually are derived from baseline and post-laser measurements of intraocular pressure during office hours in the sitting position. Only a few studies have examined the efficacy of laser trabeculoplasty beyond office hours. Although the 24-hour effect of laser trabeculoplasty has been studied ,the study was conducted before the use of these new and more potent intraocular pressure lowering drugs. So it doesn't have any study to determine the effect of selective laser trabeculoplasty and travoprost to reduce the diurnal and nocturnal variation of Iintraocular pressure.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > 18 year-old
  • Patients who were diagnosed as primary open-angle glaucoma, normal tension glaucoma, and ocular hypertension either newly diagnosed or currently on medical therapy.
  • Agree to participate in the study, accept to be randomized to receive treatment, and willing to sign an informed consent

Exclusion criteria

Related to the severity of disease and visual acuity status

  • Advance glaucoma in the study eye
  • Have a very high intraocular pressure that need immediate treatment to prevent retinal vein occlusion (intraocular pressure >30 mmHg)
  • Currently on maximal tolerated medical treatment and unable to control intraocular pressure
  • Currently on oral carbonic anhydrase inhibitor for intraocular pressure control
  • Single eye, the other eye blind from any cause

Related to surgical procedures

  • Prior laser trabeculoplasty
  • Prior glaucoma surgery
  • Prior retinal surgery
  • Underwent less than 3-month cataract extraction
  • Potential need for other ocular surgery within the 2-3-month follow-up period since enrollment Related to underlying and ocular history
  • History of diabetic retinopathy staged as severe non-proliferative or worse
  • Narrow iridocorneal angle
  • Ocular condition precluding visualization of trabecular meshwork
  • Recently have ocular inflammation of any cause
  • Previous history of ocular trauma
  • Pregnant or breast-feeding women Related to the difficulty of having reliable measurements
  • History of refractive surgery or any keratoplastic procedure
  • Corneal opacities or diseases making no suitable tonometry
  • Subjects with having poor or eccentric fixation or nystagmus
  • Excessive eye squeezing
  • Unable to lay down for measuring intraocular pressure in supine position during the night time
  • Unable to have intraocular pressure checked every 2-hour such as have complicated underlying diseases or having sleep deprivation Related to allergy
  • Known allergy to topical anesthesia
  • Known allergy to fluorescein solution
  • Known allergy to travoprost Related to compliance
  • Impairment preventing adequate understanding to sign an informed consent
  • Subject has demonstrated potential for non-compliance with the study protocol
  • Unwilling to be randomized to receive treatment
  • Unwilling to be washed out from currently treated drug(s).

Treatment and study plan

Selective laser trabeculoplasty

Device

Selective laser trabeculoplasty platform The Lumenis Selecta® Duet™ (Lumenis Ltd., Yokneam, Israel)

Other names: The Lumenis Selecta® Duet™ (Lumenis Ltd., Yokneam, Israel)

Travoprost

Drug

Travoprost benzalkonium-free ophthalmic solution (40 microgram/ml) (Alcon Laboratories, Inc., Fort Worth, TX, USA)

Other names: Travatan benzalkonium-free

Primary outcomes

  1. Change of circadian intraocular pressure

    Time frame: Six weeks after recieving treatment

    intraocular pressure values measured during daytime and nighttime, compare between selective laser trabeculoplasty and travoprost (include pre- and post-treatment intraocular pressure values)

Secondary outcomes

  1. Position related intraocular pressure

    Time frame: Six weeks after the treatments

    Intraocular pressure different when measuring in the sitting and supine position (include pre- and post-treatment intraocular pressure values

  2. Ocular surface disease

    Time frame: Six weeks after the treatments

    Using the glaucoma symptom scale-10 (GSS-10) and ocular surface disease questionnaire for evaluation

Sponsors and collaborators

Lead sponsor

Prince of Songkla University

Other

Registry information

Official study title

A Prospective, Randomized Study Comparing the Effects of Selective Laser Trabeculoplasty and Travoprost on the Circadian Intraocular Pressure Variation

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
Apr 7, 2014
Registry last updated
Aug 8, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.